Bladder cancer
- 1 May 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 17 (3) , 275-280
- https://doi.org/10.1097/01.cco.0000156985.47984.9e
Abstract
This article reviews the recent literature concerning important issues in the management of patients with bladder cancer. A brief overview of all aspects of bladder cancer including the etiology, diagnosis, and treatment are discussed with a focus on recent advances. Bladder cancer is a significant cause of morbidity and mortality. The treatment for bladder cancer should be based on individual patient risk assessment and should include a multidisciplinary approach. In patients with superficial bladder cancer, research has focused on improving and optimizing intravesical therapy to reduce tumor recurrence and progression as well as on methods to better select the most appropriate treatment for patients with high-risk features. The important prognostic and therapeutic role of lymphadenectomy during radical cystectomy has become apparent and recent work has attempted to better define what should be considered the standard for lymph node dissection. Finally, in an attempt to improve survival, advances have been made using systemic chemotherapy in both the perioperative settings as well as for treatment of metastatic bladder cancer. Research continues to improve our understanding of bladder cancer. This ongoing investigation is currently being translated to the bedside with refinements in the diagnosis and treatment of patients with bladder cancer.Keywords
This publication has 49 references indexed in Scilit:
- Alkylaniline-Hemoglobin Adducts and Risk of Non-Smoking-Related Bladder CancerJNCI Journal of the National Cancer Institute, 2004
- New molecular markers for bladder cancer detectionCurrent Opinion in Urology, 2004
- A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALSJournal of Urology, 2004
- Intravesical bacille calmette-guérin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progressionUrology, 2004
- Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trialsBJU International, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Urinary markers of bladder carcinomaClinica Chimica Acta; International Journal of Clinical Chemistry, 2003
- Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, 2002
- The impact of characteristics of cigarette smoking on urinary tract cancer riskCancer, 2000
- Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and ToxicityPublished by Wolters Kluwer Health